FDA’s Advisory Committee says no to MDMA. What’s the impact? With Josh Hardman
Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & the startups building it
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & the startups building it! 🍄
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on MDMA-assisted therapy for PTSD.
Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.
In this episode, we discuss…
The FDA advisory committee process and its implications for drug approvals
Functional unblinding and expectancy effects in psychedelic clinical trials
Potential impacts on the broader psychedelic medicine industry
The future of psychedelic-assisted psychotherapy protocols
Neuroplastogen development and non-hallucinogenic approaches
Challenges around therapy, safety, and regulatory pathways for psychedelic medicines
Listen to the episode here, on Spotify, or on Apple Podcasts.
Once you've finished the episode, we'd love to hear your thoughts! Tweet us at @psymedventures or email us at hi@psymed.ventures to share your views.
P.S. Do you know someone who would enjoy the Business Trip by PsyMed Ventures podcast? Feel free to share this newsletter by clicking the link below and hitting the ❤️ button on this post to help us reach more people on Substack 🙏